anti-CD20/CD37 monoclonal antibody combination PSB202

{
  "id": "MLC-T-ONC-010304",
  "term": "anti-CD20/CD37 monoclonal antibody combination PSB202",
  "field": "Oncology and biomedicine",
  "definition": "A combination agent composed of two humanized monoclonal antibodies, PSB102, an Fc-enhanced immunoglobulin G1 (IgG1) monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen (TAA) CD20, and PSB107, an IgG1 monoclonal antibody directed against the TAA CD37, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/CD37 monoclonal antibody combination PSB202 specifically targets and binds to CD20 and CD37 expressed on tumor cells. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD20- and CD37-expressing B cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. CD37, a member of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety of cancer cell types and plays a key role in tumor cell proliferation.",
  "synonyms": [
    "anti-CD20 monoclonal antibody/anti-CD37 monoclonal antibody combination PSB202",
    "anti-CD20/anti-CD37 monoclonal antibody combination PSB202",
    "PSB102 and PSB107",
    "PSB102 plus PSB107",
    "PSB102/PSB107"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd20-cd37-monoclonal-antibody-combination-psb202/"
}